Cancer Res Treat.
2024 Jul;56(3):972-973. 10.4143/crt.2024.019.
Bridging the Gap between Trial Adverse Events and Real-World Data
- Affiliations
-
- 1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju, Korea
- 2Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
- KMID: 2557684
- DOI: http://doi.org/10.4143/crt.2024.019
Reference
-
References
1. Jeon Y, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, et al. First-line alectinib vs. brigatinib in advanced non-small cell lung cancer with ALK rearrangement: real-world data. Cancer Res Treat. 2024; 56:61–9.
Article2. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021; 16:2091–108.
Article3. Yang JC, Liu G, Lu S, He J, Burotto M, Ahn MJ, et al. Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial. J Thorac Oncol. 2023; 18:1743–55.
Article4. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020; 31:1056–64.
Article
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Bridging the Gap between Evidence and Real-World Practice for Liver Cancer Screening in South Korea
- Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
- Safety of Adalimumab, Ustekinumab, Secukinumab, Guselkumab in Korean Patients with Moderate to Severe Psoriasis: A Real-World Data in a Single Medical Center
- Incorporation of real-world data to a clinical trial: use of external controls
- Clinical Efficacy and Safety of Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Korea: A Real-World Data in a Single Medical Center
